TITLE

World Health Organization Clinical Stage 3 disease conditions in HIV-infected patients who start antiretroviral therapy in Malawi

AUTHOR(S)
Ngoma, Damas; Makombe, Simon D.; Kamoto, Kelita; Harries, Anthony D.
PUB. DATE
July 2008
SOURCE
Tropical Doctor;Jul2008, Vol. 38 Issue 3, p159
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
There is little information about disease conditions that are diagnosed in patients diagnosed as having World Health Organization Clinical Stage 3 HIV who are started on antiretroviral therapy (ART) in Africa. We therefore conducted an audit in the central region of Malawi of patients registered for ART between January and September 2006. There were 4299 patients in Stage 3 of whom 4154 had data about their disease conditions. Only one condition was listed for 3880 patients. Of these, 1892 (48.8%) had unexplained weight loss, chronic fever or chronic diarrhoea, 822 (21.2%) had active/previous tuberculosis (TB) and 671 (17.3%) had a severe presumed bacterial infection. No patient was diagnosed as having haematological abnormalities. Nearly half the patients started on ART had a symptomatic, unspecified disease, (which may be obscuring important pathologies such as TB) and almost no laboratory assessment had taken place before the commencement of ART. These two areas need to be addressed in order to improve the management of patients starting on ART.
ACCESSION #
70244684

 

Related Articles

  • Mortality among HIV-Infected Patients in Resource Limited Settings: A Case Controlled Analysis of Inpatient's at a Community Care Center. Rajagopalan, Nirmala; Suchitra, Joyce B.; Shet, Anita; Khan, Zafar K.; Martin-Garcia, Julio; Nonnemacher, Michael R.; Jacobson, Jeffrey M.; Wigdahl, Brian // American Journal of Infectious Diseases;2009, Vol. 5 Issue 3, p219 

    Problem statement: Despite massive national efforts to scale up Antiretroviral Therapy (ART) access in India since 2004, the AIDS death rate was 17.2 per 100,000 persons during 2003- 2005. In the era of HAART in resource poor settings, it is imperative to understand and address the causes of...

  • Forecasting antiretroviral and diagnostic needs.  // WHO Drug Information;2005, Vol. 19 Issue 2, p129 

    Forecasts the accessibility of people with HIV/AIDS to antiretrovirals and diagnostics. Efforts of the World Health Organization to provide treatment to people with HIV/AIDS; Factors that are essential to the success of the WHO initiative; Examination of the best practices and problems in...

  • Scaling Up Treatment – Why We Can't Wait. Kim, Jim Yong; Gilks, Charlie // New England Journal of Medicine;12/1/2005, Vol. 353 Issue 22, p2392 

    The article presents the author's views on antiretroviral treatment programs for people living with the human immunodeficiency virus (HIV) and AIDS. HIV infection has largely become a manageable, chronic condition in countries rich in resources because of the availability of combination-drug...

  • Number of people with HIV on ART climbs to more than 5 million.  // Infectious Diseases in Children;Aug2010, Vol. 23 Issue 8, p21 

    This article reports on the increase in the number of people with human immunodeficiency virus (HIV) who initiated antiretroviral therapy in 2009, according to the World Health Organization (WHO).

  • Risk factors for discordant immune response among HIV-infected patients initiating antiretroviral therapy: A retrospective cohort study. Muzah, B. P.; Takuva, S.; Maskew, M.; Delany-Moretlwe, S. // Southern African Journal of HIV Medicine;Nov2012, Vol. 13 Issue 4, p168 

    Background. The therapeutic goal of antiretroviral therapy (ART) is sustained immune recovery and viral suppression. However, some patients experience poor CD4 cell count responses despite achieving viral suppression. Such discordant immune responses have been associated with poor clinical...

  • Quality of life of People living with HIV and AIDS attending the Antiretroviral Clinic, University College Hospital, Nigeria. Folasire, Oluyemisi F.; Irabor, Achiaka E.; Folasire, Ayorinde M. // African Journal of Primary Health Care & Family Medicine;2012, Vol. 4 Issue 1, p1 

    Background: Quality of life (QOL) is an important component in the evaluation of the well-being of people living with HIV and AIDS (PLWHA), especially with the appreciable rise in longevity of PLWHA. Moreover, limited studies have been conducted in Nigeria on how PLWHA perceive their life with...

  • Initial Virologic Response and HIV Drug Resistance Among HIV-Infected Individuals Initiating First-line Antiretroviral Therapy at 2 Clinics in Chennai and Mumbai, India. Hingankar, Nitin K.; Thorat, Smita R.; Deshpande, Alaka; Rajasekaran, S.; Chandrasekar, C.; Kumar, Suria; Srikantiah, Padmini; Chaturbhuj, Devidas N.; Datkar, Sharda R.; Deshmukh, Pravin S.; Kulkarni, Smita S.; Sane, Suvarna; Reddy, D. C. S.; Garg, Renu; Jordan, Michael R.; Kabra, Sandhya; Tripathy, Srikanth P.; Paranjape, Ramesh S. // Clinical Infectious Diseases;May2012 Supplement 4, Vol. 54 Issue suppl_4, pS348 

    Human immunodeficiency virus drug resistance (HIVDR) in cohorts of patients initiating antiretroviral therapy (ART) at clinics in Chennai and Mumbai, India, was assessed following World Health Organization (WHO) guidelines. Twelve months after ART initiation, 75% and 64.6% of participants at the...

  • Immunovirological Response to Triple Nucleotide Reverse-Transcriptase Inhibitors and Ritonavir-Boosted Protease Inhibitors in Treatment-Naïve HIV-2–Infected Patients: The ACHIEV2E Collaboration Study Group. Benard, Antoine; van Sighem, Ard; Taieb, Audrey; Valadas, Emilia; Ruelle, Jean; Soriano, Vicente; Calmy, Alexandra; Balotta, Claudia; Damond, Florence; Brun-Vezinet, Françoise; Chene, Geneviève; Matheron, Sophie // Clinical Infectious Diseases;May2011, Vol. 52 Issue 10, p1257 

    This European inter-cohort collaboration shows poorer immunological and virological responses with triple NRTI compared to PI/r-containing cART in treatment-naïve HIV-2-infected patients, regardless of baseline CD4 cell count. PI/r-containing cART should be recommended as first-line...

  • HIV guideline changes could slow virus spread.  // New Scientist;12/5/2009, Vol. 204 Issue 2737, p7 

    The article reports on the advice issued by the World Health Organization (WHO) to administer antiretroviral therapy (ART) to people with human immunodeficiency virus (HIV) earlier in the infection cycle. WHO suggests that ART be started when the levels of CD4 immune cells decreased below 200...

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics